Protara Q3 Loss Widens to $21.7M; Buys Novex Manufacturing Assets for $8.75M
TARA is trading near its 52-week low of $2.11 (0.0% above the low).
Summary
Protara posted a wider Q3 loss of $21.7 million, with $143.1 million in cash funding operations into 2028. Separately, it agreed to buy TARA-002 manufacturing assets from Novex for $8.75 million while pushing STARBORN-1 enrollment into early 2027.
Key Events · Earnings and Guidance · TARA
-
Q3 Loss Widens on Higher R&D
Net loss of $21.7 million, or $0.35 per share, versus $13.3 million, or $0.31 per share, a year earlier; R&D rose to $16.8 million from $9.6 million.
-
Cash Runway Into 2028
Unrestricted cash, equivalents and marketable debt securities totaled $143.1 million as of September 30, 2026, down from $161.9 million at June 30.
-
Novex Manufacturing Asset Purchase
On November 4, 2026, Protara agreed to buy TARA-002 manufacturing-related assets from Novex Innovations for $8.75 million, including workforce, inventory, IP, equipment and a facility lease.
-
STARBORN-1 Enrollment Slips to 1Q 2027
Enrollment in the registrational STARBORN-1 trial in lymphatic malformations is now expected to complete early in 1Q 2027, with a rolling BLA submission in 2H 2027.
Analysis · TARA · Life Sciences
Protara's Q3 net loss widened to $21.7 million from $13.3 million a year ago, with R&D spending jumping to $16.8 million from $9.6 million on higher trial costs. Cash and investments of $143.1 million are still expected to fund operations into 2028, so there is no near-term financing emergency. The more consequential item is the $8.75 million purchase of TARA-002 manufacturing assets from Novex, its clinical supply partner since 2019 — bringing production in-house ahead of a potential launch. Against that, the STARBORN-1 lymphatic malformation trial now completes enrollment in early 1Q 2027 rather than by year-end 2026, a slip that pushes the rolling BLA to 2H 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TARA was trading at $2.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.9M. The 52-week trading range was $2.11 to $7.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.